announced today that it entered into a partnership with Altegrity Risk InternationalSM
(ARI) to serve as NanoGuardian's security partner in delivering its Closed-Loop
Protection™ Program, which assists manufacturers in detecting counterfeit
and illegally diverted products in the legitimate supply chain.
NanoGuardian's Closed-Loop Protection Program works hand-in-hand with
its NanoEncryption™ technology and utilizes statistical modeling with
randomized pharmacy auditing in an effort to identify counterfeit or illegally
diverted pharmaceuticals on pharmacies' shelves awaiting distribution
to patients. The mission of NanoGuardian's Closed-Loop Protection Program
is to provide early detection of counterfeit and illegally diverted products,
helping to reduce risk to patients, brands, and companies.
“NanoGuardian is committed to forging relationships with best-of-class
partners in our effort to protect patients and brands. We are very excited to
announce another such partnership with ARI, a global leader in corporate security
with significant experience in the pharmaceutical space,” said Dean Hart,
executive vice president, NanoGuardian. “Pharmaceutical counterfeiting
and diversion are growing concerns throughout the world, and the criminals engaged
in these activities are sophisticated and well-resourced. On-dose security technologies,
such as NanoGuardian's NanoEncryption technology, that remain with every
dose indefinitely and defy counterfeit packaging, are absolutely necessary to
protect patients and brands in this escalating war. Programs such as NanoGuardian's
Closed-Loop Protection that proactively search for the emergence of counterfeit
and illegally diverted medications in the legitimate supply chain provide an
additional measure of protection and safety while reducing risks to patients,
brands, and companies. ARI's experience and the depth and breadth of its
resources are great additions to the NanoGuardian solution,” added Hart.
“We are thrilled to partner with NanoGuardian in its efforts to protect
patients by ensuring supply chain integrity,” said Thomas McWeeney, Managing
Director & Head of the Washington D.C. Office, ARI. “ARI's industry-leading
expertise and experience in security consulting, investigative intelligence,
and monitoring services make this partnership ideal given the cutting-edge protection
that NanoGuardian's NanoEncryption technology provides pharmaceutical
manufacturers. ARI will leverage our diverse resources—including more
than 2,800 cleared investigators located throughout the United States and U.S.
territories as well as our network of professionals around the globe with experience
in more than 150 countries—to ensure the chain of custody of pharmaceutical
products that are acquired as a part of the Closed-Loop Protection Program.
Given its NanoEncryption technology with the Closed-Loop Protection market monitoring
program, NanoGuardian has proven that it is at the forefront of brand protection
for the pharmaceutical industry.”
NanoGuardian's NanoEncryption fights both counterfeiting and illegal diversion
with a single technology that works directly on capsules, tablets, vial caps,
and single-use syringes to provide an intrinsic, layered security strategy of
overt, covert, and forensic security features. The overt and covert security
features allow dose-level authentication at any point in a manufacturer's supply
chain, while the forensic and nano-scale NanoCodes™ provide comprehensive
tracing information on each and every dose. NanoGuardian's technology provides
a strong benefit over other on-dose technologies given that NanoGuardian's security
features are implemented with no additional chemicals being added to the medication.